Table 1.
Patient characteristics
| Characteristic | Number | % | |
| Sex | |||
| Male | 18 | 67 | |
| Female | 9 | 33 | |
| Age, years | |||
| Mean | 61.6 | ||
| Range | (45–80) | ||
| Race/ethnicity | |||
| White | 24 | 89 | |
| Asian | 2 | 7 | |
| Black | 1 | 4 | |
| ECOG PS | |||
| 0 | 19 | 70 | |
| 1 | 8 | 30 | |
| Tumor types | |||
| Anal cancer | 1 | 4 | |
| Bladder cancer | 1 | 4 | |
| Breast cancer | 3 | 11 | |
| Colon cancer | 1 | 4 | |
| Hepatocellular carcinoma | 1 | 4 | |
| Melanoma | 11 | 41 | |
| Mesothelioma | 2 | 7 | |
| Nasopharyngeal cancer | 1 | 4 | |
| Neuroendocrine tumor | 1 | 4 | |
| Non-small cell lung cancer | 1 | 4 | |
| Ovarian cancer | 1 | 4 | |
| Renal cell carcinoma | 2 | 7 | |
| Uterine cancer | 1 | 4 | |
| Prior treatment | |||
| Chemotherapy | 26 | 96 | |
| Radiation | 13 | 48 | |
| Surgery | 27 | 100 | |
| Immunotherapy* | 4 | 15 | |
| Treatment Group | |||
| 0.05 mg/kg | 5 | 19 | |
| 0.1 mg/kg | 3 | 11 | |
| 0.2 mg/kg | 13 | 48 | |
| 0.25 mg/kg | 6 | 22 | |
*
includes interferon-alpha, IL-2, peptide vaccines, interferon-beta adenovirus gene therapy.